Colorectal Cancer Clinical Trial
— ELDERLYOfficial title:
Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Metastatic Colorectal Cancer
Verified date | February 2024 |
Source | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a controlled, open-label, randomized phase- II trial (1:1 randomization) investigating 5-FU + aflibercept and 5-FU + oxaliplatin in elderly and frail elderly patients with mCRC scheduled to receive first line treatment.
Status | Completed |
Enrollment | 124 |
Est. completion date | February 1, 2024 |
Est. primary completion date | February 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 70 Years and older |
Eligibility | Inclusion Criteria: 1. To enter this trial the oncologist has to confirm, that the patient was in his or her opinion not a candidate for standard full-dose combination therapy. Moreover, the oncologist has to state the reason for entering the trial (Advanced age alone versus both age and frailty). As an operational definition for frailty the G8 screening tool will be used upon inclusion of the patient in a standardized manner. Briefly, G8 is an established screening tool that includes seven items from the Mini Nutritional Assessment (MNA) and an age-related item (<80, 80 to 85, or 85 years). The total score can range from 0 to 17. The result on the G8 is considered abnormal if the score is =14, indicating a geriatric risk profile. 2. Patients have to have histologically confirmed mCRC with unidimensionally measurable inoperable advanced or metastatic disease 3. ECOG performance status of 2 or better. 4. Life expectancy of 3 months or longer at enrolment 5. Patients >70 years with no upper age limit 6. Previous adjuvant chemotherapy is allowed if completed more than 6 months before randomisation 7. Previous rectal (chemo)radiotherapy is allowed if completed more than 6 months before randomisation 8. Hematological status: - Neutrophils (ANC) = 1.5 x 109/L - Platelets = 100 x 109/L - Hemoglobin = 9 g/dL 9. Adequate renal function: • Serum creatinine level = 1.5 x upper limit normal (ULN) 10. Adequate liver function: - Serum bilirubin = 1.5 x upper limit normal (ULN) - Alkaline phosphatase = 2.5 x ULN (unless liver metastases are present, then < 5 x ULN in that case) - AST and ALT < 3 x ULN (unless liver metastases are present then < 5 x ULN in that case) 11. Proteinuria < 2+ (dipstick urinalysis) or = 1 g/24hour 12. Signed and dated informed consent, and willing and able to comply with protocol requirements 13. Regular follow-up feasible 14. Male patients with a partner of childbearing potential must agree to use effective contraception (Pearl Index < 1) during the course of the trial and at least 3 months after last administration of the study drug. Exclusion Criteria: 1. Prior systemic chemotherapy for mCRC 2. Other concomitant or previous malignancy, except: - Adequately treated in-situ carcinoma of the uterine cervix - Basal or squamous cell carcinoma of the skin - Cancer in complete remission for > 5 years 3. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 Days 4. History or evidence upon physical examination of CNS metastasis unless adequately treated (irradiation and no seizure with appropriate treatment) 5. Uncontrolled hypercalcemia 6. Pre-existing peripheral neuropathy (NCI grade =2) 7. Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy), 8. Treatment with any other investigational medicinal product within 28 days prior to study entry. 9. Significant cardiovascular disease: - Cardiovascular accident or myocardial infarction or unstable angina =6 months before start of study treatment - Severe cardiac arrhythmia - New York Heart Association grade =2 congestive heart failure - Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy. - History of stroke or transient ischemic attack =6 months before start of study treatment - Coronary/peripheral artery bypass graft =6 months before start of study treatment. - Deep vein thrombosis or thromboembolic events =1 month before start of study treatment 10. Patients with known allergy to any excipient to study drugs, 11. Any of the following within 3 months prior to randomization: Grade 3-4 gastrointestinal bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event. 12. Bowel obstruction. 13. Treatment with CYP3A4 inducers unless discontinued > 7 days prior to randomization 14. Known dihydropyrimidine dehydrogenase (DPD) deficiency 15. Involvement in the planning and/or conduct of the study (applies to both Sanofi staff and/or staff of sponsor and study site) 16. Patient who might be dependent on the sponsor, site or the investigator 17. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG. 18. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG]. |
Country | Name | City | State |
---|---|---|---|
Germany | Phase Drei | Aschaffenburg | |
Germany | HELIOS Klinikum Bad Saarow | Bad Saarow | |
Germany | Klinikum Bayreuth | Bayreuth | |
Germany | MVZ Seestrasse | Berlin | |
Germany | Klinikum Bremen Nord | Bremen | |
Germany | Kliniken Essen-Mitte | Essen | |
Germany | Agaplesion Markus Krankenhaus | Frankfurt | |
Germany | Krankenhaus Nordwest GmbH | Frankfurt | |
Germany | Klinikum Garmisch-Partenkirchen GmbH | Garmisch-Partenkirchen | |
Germany | Nationales Centrum für Tumorerkrankungen (NCT) | Heidelberg | |
Germany | Städtisches Klinikum Karlsruhe | Karlsruhe | |
Germany | DRK-Kliniken Nordhessen gGmbH | Kassel | |
Germany | Ortenau Klinikum Lahr | Lahr | |
Germany | Onkologisches Zentrum | Lebach | |
Germany | Klinikum Ludwigshafen | Ludwigshafen | |
Germany | Klinikum Magdeburg gGmbH | Magdeburg | |
Germany | Tagestherapiezentrum am ITM Universitätsmedizin Mannheim | Mannheim | |
Germany | Klinikum der Universität München-Großhadern | München | |
Germany | Kliniken Ostalb | Mutlangen | |
Germany | Kliniken des Landkreises Neumarkt in der Oberpfalz | Neumarkt In Der Oberpfalz | |
Germany | Studienzentrum Onkologie Ravensburg | Ravensburg | |
Germany | Clinical Research Stolberg GmbH | Stolberg | |
Germany | Klinikum Mutterhaus Trier | Trier | |
Germany | Universitätsklinikum Tübingen | Tübingen | |
Germany | Klinikum Wilhelmshaven | Wilhelmshaven |
Lead Sponsor | Collaborator |
---|---|
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Sanofi, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH |
Germany,
Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS, Parmar M, Langley RE; FOCUS2 Investigators; National Cancer Research Institute Colorectal Cancer Clinical Studies Group. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011 May 21;377(9779):1749-59. doi: 10.1016/S0140-6736(11)60399-1. Epub 2011 May 11. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival (PFS) | Rate of patients free of progression | 6 months | |
Secondary | Safety: Dose intensities of study medication | As calculated over the whole treatment duration and summarized descriptively by summary statistics. | 6 months | |
Secondary | Safety: Adverse events (AE) | AE's will be summarized by presenting the number and percentages of patients having any AE | 7 months | |
Secondary | Safety: Dose modification of study drug due to adverse events | Dose modifications, including discontinuations, will be summarized by presenting the number and percentages of patients having any dose modification | 6 months | |
Secondary | Safety: Rate of treatment discontinuation due to toxicitiy | Rate of treatment discontinuations during the study | 6 months | |
Secondary | Safety: Laboratory abnormalities | Summary of lab abnormalities as assessed in the documentation | 6 months | |
Secondary | Efficacy: Response rates | As measured by RECIST criteria v. 1.1 | 2 years | |
Secondary | Efficacy: Overall survival (OS) | OS according to Kaplan-Meier | 2 years | |
Secondary | Efficacy: PFS | PFS according to Kaplan-Meier | 2 years | |
Secondary | Patient reported outcomes (PRO): Quality of life | Quality of life (QoL) as measured by EQ-5D-5L at d1 of each cycle and on EOT. | 6 months | |
Secondary | PRO: Geriatric assessment | Geriatric assessment as measured by using G8, ADL and IADL | 6 months | |
Secondary | PRO: Overall treatment utility | Overall treatment utility is evaluated according to the principles used in the FOCUS2 trial. Cf. Seymour et al. Geriatric oncol 2013. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Not yet recruiting |
NCT05775146 -
SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases
|
Phase 2 | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 |